IDEAYA Biosciences Reports Positive Registrational Trial Results for Darovasertib, Plans H2 2026 NDA Submission

summarizeSummary

IDEAYA Biosciences reported positive Phase 2/3 registrational trial results for darovasertib, paving the way for an NDA submission in H2 2026, despite a wider net loss in Q1 2026, supported by a strong cash runway into 2030.

check_boxKey Events

• Darovasertib Registrational Trial Met Primary Endpoint

  The Phase 2/3 OptimUM-02 trial of darovasertib combination in first-line HLA*A2-negative metastatic uveal melanoma met its primary endpoint, reducing disease progression risk by 58% (HR 0.42) and improving median PFS to 6.9 months versus 3.1 months.

• NDA Submission Planned for H2 2026

  IDEAYA plans to submit a New Drug Application (NDA) for darovasertib to the FDA in the second half of 2026, leveraging the Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program.

• Strong Cash Position and Runway

  The company ended Q1 2026 with approximately $972.9 million in cash, cash equivalents, and marketable securities, maintaining its cash runway guidance into 2030.

• Pipeline Advancements and Collaborations

  Multiple other oncology programs, including IDE849 (DLL3 TOP1 ADC), IDE034 (B7H3/PTK7 bispecific TOP1 ADC), IDE892 (PRMT5), and IDE574 (KAT6/7), are advancing with new clinical milestones and collaborations, including with AstraZeneca.

auto_awesomeAnalysis

IDEAYA Biosciences announced highly positive topline results from its Phase 2/3 OptimUM-02 registrational trial for darovasertib in combination with crizotinib, meeting its primary endpoint in first-line HLA*A2-negative metastatic uveal melanoma. This significant clinical success, which includes a 58% reduction in disease progression risk and a statistically significant improvement in median progression-free survival, marks a critical de-risking event for the company's lead program. The planned NDA submission in the second half of 2026 under the FDA's Real-Time Oncology Review (RTOR) program accelerates the path to potential market approval. While the company reported a wider net loss for Q1 2026, the strong cash position of $972.9 million, with an unchanged runway into 2030, provides substantial financial stability to support these advancements. Investors should monitor the upcoming ASCO presentation for full data and the progress of the NDA submission.